Fosun International sheds real estate assets in Portugal
On a mission to shrink its international footprint and contain debt, the conglomerate has sold off property holdings in what was a key European base Key Takeaways: The building units…
Fosun Tourism travels back to home base with delisting plan
The resort operator is being absorbed back into the Fosun group via a buyout offer to minority shareholders, with a focus on China’s domestic travel market Key Takeaways: Fosun Tourism’s…
Bumpy ride for Fosun Tourism as bargain holidays on the rise
The Chinese owner of the Club Med chain and other travel brands is facing tighter tourism spending and could become a casualty of its parent’s debt problems Key Takeaways: Fosun…
Fosun Tourism’s post-Covid holiday fizzles
The resort unit of one of China’s leading conglomerates posted modest growth in the first quarter, as its broader outlook was clouded by debt issues at its parent Key Takeaways:…
Fosun International on cusp of new ‘asset-light’ era with latest sale
The conglomerate is selling its stake in multinational insurer Ageas, extending a slimming exercise touched off by a liquidity crisis in 2022 Key Takeaways: Fosun International’s total debt-to-capitalization ratio stood…
Fosun Tourism at crossroads as parent shops its two major assets
Fosun International is reportedly looking to sell some or all of its tourism unit’s Atlantis Sanya mega-resort, as well as a stake in the unit’s Club Med resort chain Key…
Is Fosun Set to Rise Again as China Reopens?
The debt-heavy conglomerate announced a fresh $1 billion in asset sales last week, as growing signs emerge that its looming debt crisis of 2022 may be recedingKey Takeaways:Fosun International announced…
Recent Articles
Fosun Tourism travels back to home base with delisting plan
1992.HK
0656.HK
Fosun Tourism at crossroads as parent shops its two major assets
1992.HK
0656.HK
RELATED ARTICLES
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK -
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK
-
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
2196.HK 600196.SHG
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
- Dalu chases rich valuation on high margins in weak real estate market
- Linklogis stuck in China’s real estate slump
-
Yibin Bank’s IPO spotlights challenges facing regional lenders
2596.HK
